Anifrolumab

Therapeutic indications

Anifrolumab is indicated for:

Moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE)

Irrespective of gender only Adults (18 years old or older)

Anifrolumab is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 300 mg once every 4 weeks

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines